Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 22Rectal Neoplasms 10Colonic Neoplasms 10Stomach Neoplasms 8Adenocarcinoma Of Esophagus 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Adenocarcinoma 6Lymphoma, Large B-Cell, Diffuse 5Cholangiocarcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasm Metastasis 4Neoplasms 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Carcinoma 3Biliary Tract Neoplasms 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Advanced Solid Tumors 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Bowel Adenocarcinoma 1Recurrence 1

Interventions

pembrolizumab 31Paclitaxel 14Carboplatin 12Cisplatin 8lenvatinib 7Pemetrexed 5olaparib 4belzutifan 4Oxaliplatin 4Fluorouracil 4Docetaxel 4Capecitabine 4patritumab deruxtecan 3Leucovorin 3Gemcitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Acetaminophen 3Saline Solution 2Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Dexamethasone 2Cetuximab 2130-nm albumin-bound paclitaxel 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Oxaliplatin × 30 days × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05239741 2026-05-22

MK-3475-C66

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
100 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡